BioSpace News Archive

Biotech Beach

Vividion Secures $82 Million to Advance Its Lead Programs into the Clinic

For Vividion, the financing round comes about a year after the company forged a $101 million collaboration with Celgene.

April 30, 2019
·
2 min read
·
Alex Keown
Job Trends

Betaliq Launches in Tampa to Focus on Glaucoma

The company launched with $6 million in equity funding, which is still open. Betaliq has two compounds in its pipeline, both which use Novaliq’s waterfree EyeSol technology for ophthalmology products.

April 30, 2019
·
2 min read
·
Mark Terry
Policy

Teva Recalls More Tainted Blood Pressure Drugs

Teva Pharmaceuticals recalled 35 lots of bulk Losartan Potassium after a known carcinogen was discovered in the active pharmaceutical ingredient.

April 30, 2019
·
2 min read
·
Alex Keown
Business

Increasing Revlimid Sales Drive Strong Quarter for Celgene

Celgene, which will become part of Bristol-Myers Squibb later this year, saw positive growth in the first quarter of the year.

April 30, 2019
·
3 min read
·
Alex Keown
Drug Development

Cidara Tackles Anti-Fungal Therapies, Takes Aim at Universal Flu Treatment

While few drug developers are focused on multi-drug resistant invasive fungal infections, San Diego-based Cidara Therapeutics is in the thick of the fight with its Phase III lead antifungal rezafungin.

April 30, 2019
·
3 min read
·
Alex Keown
Business

NHS England Teams with Gilead, Merck and AbbVie to Eliminate Hepatitis C

NHS England will acquire hepatitis C drugs from the companies at competitive prices and work to identify patients around the country.

April 30, 2019
·
3 min read
·
Mark Terry
Business

Following Reorganization, Pfizer Posts Growth in First Quarter

Pfizer closed out the first quarter of 2019 with revenues of $13.1 billion driven by a significant 36 percent global growth of Eliquis sales, a 34 percent increase in Xeljanz revenue and a 25 percent increase in sales of Ibrance, the company announced this morning.

April 30, 2019
·
3 min read
·
Alex Keown
BioMidwest

Reports: Odds of Getting Drugs to Market Range from 6% to 40%

Whenever drug companies come under criticism for the cost of their drugs, one of the defenses touted is that only about one in 10 drugs make it to market. As a broad figure, that’s probably about right, although at least one report ranks it higher, while another provides a bit more nuance.

April 30, 2019
·
3 min read
·
Mark Terry
BioCapital

Top Life Science Companies Hiring Now in May

According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don’t stop looking. You never know what may come your way!

April 30, 2019
·
1 min read
·
Editorial Staff
Pharm Country

Measuring the Effects of Poverty on Babies’ Brain Development

Kimberly Noble, associate professor of Neuroscience and Education at Teachers College, Columbia University, is conducting research on how socioeconomic inequality affects children’s cognitive and brain development.

April 30, 2019
·
3 min read
·
Mark Terry